Aureli Luquero

Aureli Luquero

Auto-generated profile, based on publicly available information

Aureli Luquero

Molecular Pathology and Therapeutic of Ischemic and Atherothrombotic Diseases, Institut de Recerca Sant Pau (IR-Sant Pau) , C/Sant Quintí 77-79, Barcelona 08041

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2020 in Cardiovascular Research
Verified
Journal Article
Closed access
Lina BadimonLina Badimon
Lina Badimon
ALAureli Luquero
Aureli Luquero
JCJavier Crespo
Javier Crespo
EPEsther Peña
Esther Peña
MBMaria Borrell-Pages
Maria Borrell-Pages
Aims: Atherosclerosis, the leading cause of cardiovascular diseases, is driven by high blood cholesterol levels and chronic inflammation. Low-density lipoprotein receptors (LDLR) play a critical role in regulating blood cholesterol levels by binding to and clearing LDLs from the circulation. The disruption of the interaction between proprotein convertase subtilisin/kexin 9 (PCSK9) and LDLR reduces blood cholesterol levels. It is not well known whether other members of the LDLR superfamily may be targets of PCSK9. The aim of this work was to determine if LDLR-related protein 5 (LRP5) is a PCSK9 target and to study the role of PCSK9 and LRP5 in foam cell formation and lipid accumulation. Methods and results: Primary cultures of human inflammatory cells (monocytes and macrophages) were silenced for LRP5 or PCSK9 and challenged with LDLs. We first show that LRP5 is needed for macrophage lipid uptake since LRP5-silenced macrophages show less intracellular CE accumulation. In macrophages, internalization of LRP5-bound LDL is already highly evident after 5 h of LDL incubation and lasts up to 24 h; however, in the absence of both LRP5 and PCSK9, there is a strong reduction of CE accumulation indicating a role for both proteins in lipid uptake. Immunoprecipitation experiments show that LRP5 forms a complex with PCSK9 in lipid-loaded macrophages. Finally, PCSK9 participates in TLR4/NFkB signalling; a decreased TLR4 protein expression levels and a decreased nuclear translocation of NFκB were detected in PCSK9 silenced cells after lipid loading, indicating a downregulation of the TLR4/NFκB pathway. Conclusion: Our results show that both LRP5 and PCSK9 participate in lipid uptake in macrophages. In the absence of LRP5, there is a reduced release of PCSK9 indicating that LRP5 also participates in the mechanism of release of soluble PCSK9. Furthermore, PCSK9 up-regulates TLR4/NFκB favouring inflammation.

10 August 2018 in Nano Letters
Verified
Journal Article
Closed access
PMPedro Melgar-Lesmes
Pedro Melgar-Lesmes
ALAureli Luquero
Aureli Luquero
MPMarina Parra-Robert
Marina Parra-Robert
AMAdriana Mora
Adriana Mora
JRJordi Ribera
Jordi Ribera
WJWladimiro Jiménez
Wladimiro Jiménez

26 October 2023 in Cardiovascular Research
Verified
Journal Article
Closed access
PDF file
MBMaria Borrell-Pages
Maria Borrell-Pages
ALAureli Luquero
Aureli Luquero
GVGemma Vilahur
Gemma Vilahur
TPTeresa Padró
Teresa Padró
Lina BadimonLina Badimon
Lina Badimon
There is little information on the regulation of cholesterol homeostasis in the brain. Whether cholesterol crosses the blood-brain barrier is under investigation, but the present understanding is that cholesterol metabolism in the brain is independent from that in peripheral tissues. Lipoprotein receptors from the LDL receptor family (LRPs) have key roles in lipid particle accumulation in cells involved in vascular and cardiac pathophysiology, however, their function on neural cells is unknown. The expression of LRP5 and components and targets of its downstream signaling pathway, the canonical WNT pathway including β-catenin, LEF1, VEGF, OPN MMP7 and ADAM10 is analyzed in brains of Wt and Lrp5-/- mice and in a neuroblastoma cell line. LRP5 expression is increased in a time-dependent and dose-dependent manner after lipid loading in neuronal cells; however it does not participate in cholesterol homeostasis as shown by intracellular lipid accumulation analyses. Neurons challenged with stausporin and H2O2 display an anti-apoptotic protective role for LRP5. We show for the first time that neurons can accumulate intracellular lipids and that lipid uptake is performed mainly by the LDLR while CD36, LRP1, and LRP5 do not play a major role. We also show that LRP5 triggers the canonical WNT pathway in neuronal cells to generate pro-survival signals. Finally we show, that Lrp5-/- mice have maintained expression of LRP5 only in the brain supporting the biological plausible concept of the need of brain LRP5 to elicit pro-survival processes and embryonic viability.

3 October 2025 in European Heart Journal
Verified
Journal Article
Closed access
ALAureli Luquero
Aureli Luquero
NPNoelia Pimentel
Noelia Pimentel
Gemma VilahurGemma Vilahur
Gemma Vilahur
MBMaria Borrell-Pages
Maria Borrell-Pages
Lina BadimonLina Badimon
Lina Badimon
Background and Aims: Platelets are essential for haemostasis, thrombosis, and inflammation, with their functions controlled by receptor signalling pathways. This study examined the role of LRP5, a member of the Wnt signalling cascade, in platelet function and haemostasis. Methods: Human platelets, as well as platelets isolated from wild-type (Wt) and Lrp5-deficient (Lrp5−/−) mice, were challenged with ADP, collagen, LRP5-specific inhibitors, and standard platelet inhibitor drugs. Results: Both platelet aggregation (LTA) and flow-dependent platelet deposition on collagen-coated surfaces were significantly lower in Lrp5−/− than in Wt mice. In vivo carotid artery occlusion time measured by real-time blood flow monitoring was significantly prolonged in Lrp5−/− mice. While GPVI signalling remained intact, Lrp5−/− platelets displayed reduced α- and dense granule release after ADP stimulation, along with reduced membrane levels of purinergic receptors. VASP phosphorylation confirmed that P2Y12 downstream signalling pathway was dysfunctional in the LRP5-deficient platelets. Finally, human platelets express high levels of LRP5 and flow-mediated human platelet deposition and LTA was highly reduced by LRP5 inhibition. Under the experimental conditions tested, LRP5 deletion did not significantly affect coagulation nor induce bleeding. Conclusions: These findings reveal for the first time that LRP5 plays a critical role in platelet adhesion and thrombus formation. Genetic deletion and biochemical inhibition of LRP5 markedly impair platelet aggregation and thrombosis in preclinical models, without major effects on haemostasis. Although further research is needed to evaluate its clinical applicability, LRP5 appears as a novel and actionable target to modulate platelet reactivity and thrombosis.